FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217143150> ?p ?o ?g. }

• W3217143150 endingPage "228" @default.
• W3217143150 startingPage "218" @default.
• W3217143150 abstract "Macrophage activation-like syndrome (MALS) and complex immune dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We aimed to investigate the effect of personalized immunotherapy on clinical improvement of critical COVID-19.In this open-label prospective trial, 102 patients with ARDS by SARS-CoV-2 were screened for MALS (ferritin >4,420 ng/mL) and CID (ferritin ≤4,420 ng/mL and low human leukocyte antigen (HLA)-DR expression on CD14-monocytes). Patients with MALS or CID with increased aminotransferases received intravenous anakinra; those with CID and normal aminotransferases received tocilizumab. The primary outcome was ≥25% decrease in the Sequential Organ Failure Assessment (SOFA) score and/or 50% increase in the respiratory ratio by day 8; 28-day mortality, change of SOFA score by day 28, serum biomarkers, and cytokine production by mononuclear cells were secondary endpoints.The primary study endpoint was met in 58.3% of anakinra-treated patients and in 33.3% of tocilizumab-treated patients (p: 0.01). Most patients in both groups received dexamethasone as standard of care. No differences were found in secondary outcomes, mortality, and SOFA score changes. Ferritin decreased among anakinra-treated patients; interleukin-6, soluble urokinase plasminogen activator receptor, and HLA-DR expression increased among tocilizumab-treated patients. Survivors by day 28 who received anakinra were distributed to lower severity levels of the WHO clinical progression scale. Greater incidence of secondary infections was found with tocilizumab treatment.Immune assessment resulted in favorable anakinra responses among critically ill patients with COVID-19 and features of MALS." @default.
• W3217143150 created "2021-12-06" @default.
• W3217143150 creator A5003588440 @default.
• W3217143150 creator A5003611982 @default.
• W3217143150 creator A5005905582 @default.
• W3217143150 creator A5006111907 @default.
• W3217143150 creator A5008194009 @default.
• W3217143150 creator A5008539658 @default.
• W3217143150 creator A5009238813 @default.
• W3217143150 creator A5016776205 @default.
• W3217143150 creator A5025070508 @default.
• W3217143150 creator A5025201893 @default.
• W3217143150 creator A5027955775 @default.
• W3217143150 creator A5028120366 @default.
• W3217143150 creator A5030219128 @default.
• W3217143150 creator A5034628447 @default.
• W3217143150 creator A5035007192 @default.
• W3217143150 creator A5041892423 @default.
• W3217143150 creator A5042908346 @default.
• W3217143150 creator A5044477898 @default.
• W3217143150 creator A5056134447 @default.
• W3217143150 creator A5058925599 @default.
• W3217143150 creator A5059679979 @default.
• W3217143150 creator A5060621275 @default.
• W3217143150 creator A5061573820 @default.
• W3217143150 creator A5071578233 @default.
• W3217143150 creator A5071706658 @default.
• W3217143150 creator A5075932147 @default.
• W3217143150 creator A5076332419 @default.
• W3217143150 creator A5077543058 @default.
• W3217143150 creator A5079463491 @default.
• W3217143150 creator A5082925950 @default.
• W3217143150 creator A5085995110 @default.
• W3217143150 creator A5086464424 @default.
• W3217143150 date "2021-12-01" @default.
• W3217143150 modified "2023-10-18" @default.
• W3217143150 title "ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients" @default.
• W3217143150 cites W2177407033 @default.
• W3217143150 cites W2756170974 @default.
• W3217143150 cites W2911371912 @default.
• W3217143150 cites W3009859788 @default.
• W3217143150 cites W3016288338 @default.
• W3217143150 cites W3021637159 @default.
• W3217143150 cites W3022721402 @default.
• W3217143150 cites W3023088605 @default.
• W3217143150 cites W3025045885 @default.
• W3217143150 cites W3030325615 @default.
• W3217143150 cites W3034858522 @default.
• W3217143150 cites W3037117352 @default.
• W3217143150 cites W3037768701 @default.
• W3217143150 cites W3044321702 @default.
• W3217143150 cites W3045102697 @default.
• W3217143150 cites W3087732369 @default.
• W3217143150 cites W3093604087 @default.
• W3217143150 cites W3094609299 @default.
• W3217143150 cites W3102488036 @default.
• W3217143150 cites W3108005071 @default.
• W3217143150 cites W3110844195 @default.
• W3217143150 cites W3113314881 @default.
• W3217143150 doi "https://doi.org/10.1159/000519090" @default.
• W3217143150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34852352" @default.
• W3217143150 hasPublicationYear "2021" @default.
• W3217143150 type Work @default.
• W3217143150 sameAs 3217143150 @default.
• W3217143150 citedByCount "15" @default.
• W3217143150 countsByYear W32171431502022 @default.
• W3217143150 countsByYear W32171431502023 @default.
• W3217143150 crossrefType "journal-article" @default.
• W3217143150 hasAuthorship W3217143150A5003588440 @default.
• W3217143150 hasAuthorship W3217143150A5003611982 @default.
• W3217143150 hasAuthorship W3217143150A5005905582 @default.
• W3217143150 hasAuthorship W3217143150A5006111907 @default.
• W3217143150 hasAuthorship W3217143150A5008194009 @default.
• W3217143150 hasAuthorship W3217143150A5008539658 @default.
• W3217143150 hasAuthorship W3217143150A5009238813 @default.
• W3217143150 hasAuthorship W3217143150A5016776205 @default.
• W3217143150 hasAuthorship W3217143150A5025070508 @default.
• W3217143150 hasAuthorship W3217143150A5025201893 @default.
• W3217143150 hasAuthorship W3217143150A5027955775 @default.
• W3217143150 hasAuthorship W3217143150A5028120366 @default.
• W3217143150 hasAuthorship W3217143150A5030219128 @default.
• W3217143150 hasAuthorship W3217143150A5034628447 @default.
• W3217143150 hasAuthorship W3217143150A5035007192 @default.
• W3217143150 hasAuthorship W3217143150A5041892423 @default.
• W3217143150 hasAuthorship W3217143150A5042908346 @default.
• W3217143150 hasAuthorship W3217143150A5044477898 @default.
• W3217143150 hasAuthorship W3217143150A5056134447 @default.
• W3217143150 hasAuthorship W3217143150A5058925599 @default.
• W3217143150 hasAuthorship W3217143150A5059679979 @default.
• W3217143150 hasAuthorship W3217143150A5060621275 @default.
• W3217143150 hasAuthorship W3217143150A5061573820 @default.
• W3217143150 hasAuthorship W3217143150A5071578233 @default.
• W3217143150 hasAuthorship W3217143150A5071706658 @default.
• W3217143150 hasAuthorship W3217143150A5075932147 @default.
• W3217143150 hasAuthorship W3217143150A5076332419 @default.
• W3217143150 hasAuthorship W3217143150A5077543058 @default.
• W3217143150 hasAuthorship W3217143150A5079463491 @default.
• W3217143150 hasAuthorship W3217143150A5082925950 @default.

• next